Literature DB >> 21217773

Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma.

J Ban1, G Jug, P Mestdagh, R Schwentner, M Kauer, D N T Aryee, K-L Schaefer, F Nakatani, K Scotlandi, M Reiter, D Strunk, F Speleman, J Vandesompele, H Kovar.   

Abstract

EWS-FLI1 is a chromosome translocation-derived chimeric transcription factor that has a central and rate-limiting role in the pathogenesis of Ewing's sarcoma. Although the EWS-FLI1 transcriptomic signature has been extensively characterized on the mRNA level, information on its impact on non-coding RNA expression is lacking. We have performed a genome-wide analysis of microRNAs affected by RNAi-mediated silencing of EWS-FLI1 in Ewing's sarcoma cell lines, and differentially expressed between primary Ewing's sarcoma and mesenchymal progenitor cells. Here, we report on the identification of hsa-mir-145 as the top EWS-FLI1-repressed microRNA. Upon knockdown of EWS-FLI1, hsa-mir-145 expression dramatically increases in all Ewing's sarcoma cell lines tested. Vice versa, ectopic expression of the microRNA in Ewing's sarcoma cell lines strongly reduced EWS-FLI1 protein, whereas transfection of an anti-mir to hsa-mir-145 increased the EWS-FLI1 levels. Reporter gene assays revealed that this modulation of EWS-FLI1 protein was mediated by the microRNA targeting the FLI1 3'-untranslated region. Mutual regulations of EWS-FLI1 and hsa-mir-145 were mirrored by an inverse correlation between their expression levels in four of the Ewing's sarcoma cell lines tested. Consistent with the role of EWS-FLI1 in Ewing's sarcoma growth regulation, forced hsa-mir-145 expression halted Ewing's sarcoma cell line growth. These results identify feedback regulation between EWS-FLI1 and hsa-mir-145 as an important component of the EWS-FLI1-mediated Ewing's sarcomagenesis that may open a new avenue to future microRNA-mediated therapy of this devastating malignant disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21217773      PMCID: PMC4959567          DOI: 10.1038/onc.2010.581

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  40 in total

1.  Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro.

Authors:  Dave N T Aryee; Stephan Niedan; Maximilian Kauer; Raphaela Schwentner; Idriss M Bennani-Baiti; Jozef Ban; Karin Muehlbacher; Michael Kreppel; Robert L Walker; Paul Meltzer; Christopher Poremba; Reinhard Kofler; Heinrich Kovar
Journal:  Cancer Res       Date:  2010-05-04       Impact factor: 12.701

Review 2.  Non-coding RNAs: regulators of disease.

Authors:  Ryan J Taft; Ken C Pang; Timothy R Mercer; Marcel Dinger; John S Mattick
Journal:  J Pathol       Date:  2010-01       Impact factor: 7.996

3.  Downstream EWS/FLI1 - upstream Ewing's sarcoma.

Authors:  Heinrich Kovar
Journal:  Genome Med       Date:  2010-01-28       Impact factor: 11.117

4.  Modulation of microRNA processing by p53.

Authors:  Hiroshi I Suzuki; Kaoru Yamagata; Koichi Sugimoto; Takashi Iwamoto; Shigeaki Kato; Kohei Miyazono
Journal:  Nature       Date:  2009-07-23       Impact factor: 49.962

5.  Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours.

Authors:  H Kovar; A Auinger; G Jug; D Aryee; A Zoubek; M Salzer-Kuntschik; H Gadner
Journal:  Oncogene       Date:  1993-10       Impact factor: 9.867

6.  miR-145 inhibits breast cancer cell growth through RTKN.

Authors:  Shihua Wang; Chunjing Bian; Zhuo Yang; Ye Bo; Jing Li; Lifen Zeng; Hong Zhou; Robert Chunhua Zhao
Journal:  Int J Oncol       Date:  2009-05       Impact factor: 5.650

7.  miR-145 directs intestinal maturation in zebrafish.

Authors:  Lei Zeng; Alyson D Carter; Sarah J Childs
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-05       Impact factor: 11.205

8.  Prediction of mammalian microRNA targets.

Authors:  Benjamin P Lewis; I-hung Shih; Matthew W Jones-Rhoades; David P Bartel; Christopher B Burge
Journal:  Cell       Date:  2003-12-26       Impact factor: 41.582

9.  A molecular function map of Ewing's sarcoma.

Authors:  Maximilian Kauer; Jozef Ban; Reinhard Kofler; Bob Walker; Sean Davis; Paul Meltzer; Heinrich Kovar
Journal:  PLoS One       Date:  2009-04-30       Impact factor: 3.240

10.  MicroRNA-145 targets YES and STAT1 in colon cancer cells.

Authors:  Lea H Gregersen; Anders B Jacobsen; Lisa B Frankel; Jiayu Wen; Anders Krogh; Anders H Lund
Journal:  PLoS One       Date:  2010-01-21       Impact factor: 3.240

View more
  45 in total

1.  EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance.

Authors:  Tyler P Robin; Anna Smith; Erin McKinsey; Lisa Reaves; Paul Jedlicka; Heide L Ford
Journal:  Mol Cancer Res       Date:  2012-06-20       Impact factor: 5.852

Review 2.  Molecular mechanisms of ETS transcription factor-mediated tumorigenesis.

Authors:  Adwitiya Kar; Arthur Gutierrez-Hartmann
Journal:  Crit Rev Biochem Mol Biol       Date:  2013-09-25       Impact factor: 8.250

3.  The potential value of miR-1 and miR-374b as biomarkers for colorectal cancer.

Authors:  Xiaobing Wu; Shuling Li; Xuehu Xu; Shangbiao Wu; Rong Chen; Qingping Jiang; Yong Li; Yuandong Xu
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 4.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

5.  Systems Biology Analysis for Ewing Sarcoma.

Authors:  Marianyela Petrizzelli; Jane Merlevede; Andrei Zinovyev
Journal:  Methods Mol Biol       Date:  2021

Review 6.  MicroRNAs in the pathobiology of sarcomas.

Authors:  Anne E Sarver; Subbaya Subramanian
Journal:  Lab Invest       Date:  2015-06-29       Impact factor: 5.662

Review 7.  MicroRNA expression and its clinical implications in Ewing's sarcoma.

Authors:  Zheng Li; Xin Yu; Jianxiong Shen; William Ka Kei Wu; Matthew T V Chan
Journal:  Cell Prolif       Date:  2014-12-22       Impact factor: 6.831

8.  MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients.

Authors:  Kai Doberstein; Nico Steinmeyer; Ann-Kathrin Hartmetz; Wolfgang Eberhardt; Michel Mittelbronn; Patrick N Harter; Eva Juengel; Roman Blaheta; Josef Pfeilschifter; Paul Gutwein
Journal:  Neoplasia       Date:  2013-02       Impact factor: 5.715

9.  The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma.

Authors:  J K Parrish; M Sechler; R A Winn; P Jedlicka
Journal:  Oncogene       Date:  2013-12-23       Impact factor: 9.867

Review 10.  MicroRNA-mediated gene regulations in human sarcomas.

Authors:  Subbaya Subramanian; Reena V Kartha
Journal:  Cell Mol Life Sci       Date:  2012-08-25       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.